Replimune Appoints New CMO and CDO, Chief Medical Officer Departs
Ticker: REPL · Form: 8-K · Filed: 2024-03-26T00:00:00.000Z
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Replimune shakes up leadership: new CMO & CDO in, old CMO out.
AI Summary
Replimune Group, Inc. announced on March 21, 2024, the appointment of Dr. Philip Astley-Sparke as Chief Medical Officer and Dr. Robert Burns as Chief Development Officer. The company also reported the departure of Dr. Robert Smallwood as Chief Medical Officer. These changes are effective immediately.
Why It Matters
Key leadership changes in medical and development roles can signal shifts in strategic direction or execution for a biotechnology company focused on novel cancer immunotherapies.
Risk Assessment
Risk Level: medium — Leadership changes, especially in critical roles like Chief Medical Officer and Chief Development Officer, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant
- Dr. Philip Astley-Sparke (person) — Appointed Chief Medical Officer
- Dr. Robert Burns (person) — Appointed Chief Development Officer
- Dr. Robert Smallwood (person) — Departed Chief Medical Officer
- March 21, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer at Replimune Group, Inc.?
Dr. Philip Astley-Sparke has been appointed as the new Chief Medical Officer.
What is the effective date of the leadership changes at Replimune?
The changes are effective as of March 21, 2024.
Who has been appointed as the Chief Development Officer?
Dr. Robert Burns has been appointed as the Chief Development Officer.
Who has departed from their role as Chief Medical Officer?
Dr. Robert Smallwood has departed from his role as Chief Medical Officer.
What is the principal executive office address for Replimune Group, Inc.?
The address is 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801.
Filing Stats: 2,367 words · 9 min read · ~8 pages · Grade level 11.6 · Accepted 2024-03-26 07:33:29
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
- $600,000 — led to an initial annual base salary of $600,000 and is eligible to receive an annual di
- $268,686 — led to an initial annual base salary of $268,686 and is eligible to receive an annual di
Filing Documents
- tm249769d1_8k.htm (8-K) — 44KB
- tm249769d1_ex99-1.htm (EX-99.1) — 13KB
- 0001104659-24-038705.txt ( ) — 238KB
- repl-20240321.xsd (EX-101.SCH) — 3KB
- repl-20240321_lab.xml (EX-101.LAB) — 33KB
- repl-20240321_pre.xml (EX-101.PRE) — 22KB
- tm249769d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of Directors;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2024, Replimune Group, Inc. (the "Company") issued a press release announcing that Dr. Sushil Patel, the Company's current chief strategy officer, has been appointed as the Company's chief executive officer, effective as of April 1, 2024 (the "Effective Date"). In connection with Dr. Patel's promotion to the Company's chief executive officer, effective as of the Effective Date, (i) Dr. Patel has been appointed to join the Company's Board of Directors (the "Board") to serve as a Class III director, (ii) Philip Astley-Sparke, the Company's current chief executive officer, will transition to the role of executive chairman of the Board and (iii) Dieter Weinand, the Company's current chair of the Board, will transition into the newly created role of the lead independent director of the Board (the foregoing, collectively, the "CEO Transition"). In addition to the CEO Transition, the Company announced certain other executive leadership transitions. Specifically, (i) Dr. Robert Coffin, who serves as a member of the Board and is the Company's current president and chief research & development officer, will transition to an advisory role as founder and chief scientist, effective April 1, 2024, (ii) Dr. Colin Love, the Company's current chief operating officer, will retire from the Company, effective May 31, 2024, (iii) Dr. Pamela Esposito, the Company's current chief business officer, and Tanya Lewis, the Company's current chief development operations officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity and (v) Paul Bullock, the Company's current senior vice president, operations and Framingham site head, is being promoted to the Company's chief manufacturing officer effective April 1, 2024 (the foregoing, collectively, the "Executive
01 Other Events
Item 8.01 Other Events. The disclosure in Item 5.02 in respect of the Executive Leadership Transitions is incorporated by reference in this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 News Release dated March 26, 2024 104 Cover page interactive data file (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: March 26, 2024 By: /s/ Philip Astley-Sparke Philip Astley-Sparke Chief Executive Officer